HOPKINTON, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. , a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS(R) Kinetic preclinical in vivo imaging system. The system enables researchers to non-invasively view biological events at the molecular level as they occur in real-time. The IVIS Kinetic system utilizes the latest developments in ultra-high sensitivity scientific cameras to add video capability to the company’s existing line of preclinical, high sensitivity bioluminescence and fluorescence molecular optical imaging offerings. This additional capability will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted using in vivo imaging.
With the launch of the IVIS Kinetic system, researchers are now able to visualize, track, quantify and understand biological processes in real time-as the action happens-driving visual exploration and analysis of gene expression, cellular pathways and drug response. The IVIS Kinetic system features an isolation chamber that allows users to monitor conscious mice freely walking and performing tasks. By capturing images and live video, at the molecular level, researchers can witness dynamic processes and reactions, enhancing the understanding of a drug candidate’s potential performance in clinical studies. Specifically, by allowing researchers to view the real-time distribution of drugs and an animal model’s responses to a compound, a more thorough understanding of a drug’s potential can be assessed.
“The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen,” said Kevin Hrusovsky, president and chief executive officer, Caliper Life Sciences. “This system is another great example of how Caliper Life Sciences is helping pharma and biotech companies understand complex biological processes to accelerate the discovery of successful drug candidates.”
Caliper’s IVIS imaging systems have played a significant role in demonstrating the efficacy of various drugs, including Sutent(R) (Pfizer), Sprycel(R) (dasatinib) (Bristol-Myers Squibb), Tasigna(R) (Novartis), and Cubicin(R) (Cubist Pharmaceuticals).
Caliper offers a broad portfolio of imaging systems. For additional information or to order the IVIS Kinetic, please visit: http://www.caliperls.com/products/optical-imaging/.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.
Caliper and IVIS are registered trademarks of Caliper Life Sciences, Inc. Sutent is a registered trademark of Pfizer, Inc. Sprycel(R) is a registered trademark of Bristol-Myers Squibb. Tasigna is a registered trademark of Novartis. Cubicin is a registered trademark of Cubist Pharmaceuticals.
CONTACT: Investor Contact: Peter F. McAree of Caliper Life Sciences,
+1-508-497-2215; or Media Contact: Stacey Holifield or Tim Pitta of
Schwartz Communications, +1-781-684-0770, caliper@schwartz-pr.com, for
Caliper Life Sciences, Inc.
Web site: http://www.caliperls.com/
